Neuralink’s mind-blowing milestone: FDA gives Elon Musk’s brain-implant venture green light

AP Photo/Michel Euler, Pool, File

The US Food and Drug Administration (FDA) has approved Neuralink, Elon Musk’s brain-implant company, to start its first-in-human clinical trial. This marks a significant milestone for the company, which had previously faced challenges in obtaining approval.

In a tweet, Neuralink stated that the FDA’s decision was an essential first step towards helping many people through their technology, though further details on the study have yet to be revealed.

Neuralink’s brain implants are envisioned to potentially cure a variety of conditions, such as obesity, autism, depression, and schizophrenia, as well as enable web browsing and telepathy. Musk previously expressed his confidence in the safety of the devices, even stating his willingness to implant them in his children.

Despite Musk’s predictions since 2019 that Neuralink would begin human trials, the company only sought FDA approval in early 2022. The application was initially rejected, with the FDA citing concerns over the device’s lithium battery, the potential migration of the implant’s wires within the brain, and the challenge of safely removing the device without causing brain tissue damage.

Founded in 2016, Neuralink has been the subject of multiple federal investigations.

In May, US lawmakers called for regulators to examine whether the composition of a panel overseeing animal testing at Neuralink contributed to flawed and rushed experiments. Additionally, the Department of Transportation is investigating whether the company illegally transported dangerous pathogens on chips removed from monkey brains without proper containment measures.

Furthermore, the US Department of Agriculture’s Office of Inspector General is probing potential animal-welfare violations at Neuralink and scrutinising the USDA’s oversight of the company. Neuralink has not commented on these investigations, reports Channel News Asia.

Business NewsWorld News

Alex Morgan

Alex is a 42-year-old former corporate executive and business consultant with a degree in business administration. Boasting over 15 years of experience working in various industries, including technology, finance, and marketing, Alex has acquired in-depth knowledge about business strategies, management principles, and market trends. In recent years, Alex has transitioned into writing business articles and providing expert commentary on business-related issues. Fluent in English and proficient in data analysis, Alex strives to deliver well-researched and insightful content to readers, combining practical experience with a keen analytical eye to offer valuable perspectives on the ever-evolving business landscape.

Related Articles